Clinical Trials Related to Ovarian Cancer

Related studies linked through entity extraction aliases.

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Status: TERMINATED
Phase: PHASE1/PHASE2

Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing

Status: COMPLETED
Phase: NA

4FMFES-PET Imaging of Endometrial and Ovarian Cancers

Status: COMPLETED
Phase: PHASE1/PHASE2

Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System

Status: COMPLETED
Phase: N/A

Spectroscopy in Ovarian Cancer

Status: COMPLETED
Phase: N/A

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Status: UNKNOWN
Phase: PHASE2

A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Status: TERMINATED
Phase: PHASE1/PHASE2

Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test

Status: UNKNOWN
Phase: N/A

Phase 1 Dose Escalation of ArtemiCoffee

Status: COMPLETED
Phase: PHASE1

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Status: COMPLETED
Phase: PHASE1

Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers

Status: WITHDRAWN
Phase: PHASE2/PHASE3

Prehabilitation in Gynaecological Cancer Patients

Status: RECRUITING
Phase: PHASE3

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

Status: RECRUITING
Phase: PHASE2

Real-life Use of Niraparib in a Patient Access Program in Norway

Status: COMPLETED
Phase: N/A

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab

Status: UNKNOWN
Phase: N/A

The Culture of Ovarian Cancer Organoids and Drug Screening

Status: UNKNOWN
Phase: N/A

Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

Status: UNKNOWN
Phase: N/A

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

Status: RECRUITING
Phase: PHASE1/PHASE2

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Status: RECRUITING
Phase: NA